Entry level $132.59 = Target price $138.82 = Stop loss $130.66
7&12 MA's cross imminent.
Sarepta Therapeutics could very well continue to surge on the FDA approval.
7&12 MA's cross imminent.
Sarepta Therapeutics could very well continue to surge on the FDA approval.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.